Tehran University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share this content! On (X network) By
Pegylation of Cationic Liposomes Encapsulating Soluble Leishmania Antigens Reduces the Adjuvant Efficacy of Liposomes in Murine Model Publisher Pubmed



Naseri H1 ; Eskandari F1 ; Jaafari MR1, 2, 3 ; Khamesipour A4 ; Abbasi A1 ; Badiee A1, 3
Authors
Show Affiliations
Authors Affiliations
  1. 1. Nanotechnology Research Center, Mashhad University of Medical Sciences, Mashhad, Iran
  2. 2. Biotechnology Research Center, Mashhad University of Medical Sciences, Mashhad, Iran
  3. 3. Department of Pharmaceutical Nanotechnology, School of Pharmacy, Mashhad University of Medical Sciences, Mashhad, Iran
  4. 4. Center for Research and Training in Skin Diseases and Leprosy, Tehran University of Medical Sciences, Tehran, Iran

Source: Parasite Immunology Published:2017


Abstract

Although there have been several attempts to develop a vaccine against leishmaniasis, no vaccine in human has been developed yet. Liposomes consisting of 1, 2-dioleoyl-3-trimethylammonium-propane (DOTAP) encapsulating soluble Leishmania antigens (SLA) enhance protective immunity of SLA against Leishmania major infection in mice. However, they immobilized at the injection site because of their positive charge. To overcome the problem, shielding the surface charge with polyethylene glycol (PEGylation) was chosen in this study. Liposomal SLA consisting different concentrations of PEG (1.9%-15% mol) were prepared. BALB/c mice were immunized three times in 3 weeks intervals with different formulations. Lesion development and parasite burden in footpad and spleen were evaluated to specify the type of generated immune response and extent of protection. Th1/Th2 cytokine profiles and IgG isotypes were also analysed. The maximum protection was observed in mice immunized with Lip-SLA or pLip-SLA (1.9%) due to smaller footpad swelling, reduction in parasite load, an increase in IgG2a and IFN-γ production. Our results showed that immunization of mice with a high level of PEG (>7.5%) did not improve protective immunity of liposomal SLA. The presence of PEG, particularly more than 3.75%, is not recommended for protection against leishmaniasis. © 2017 John Wiley & Sons Ltd
Related Docs
View other Related Docs
1. The Role of Iscomatrix Bilayer Composition to Induce a Cell Mediated Immunity and Protection Against Leishmaniasis in Balb/C Mice, Iranian Journal of Basic Medical Sciences (2016)
2. Development of Nano-Carriers for Leishmania Vaccine Delivery, Expert Opinion on Drug Delivery (2020)
3. The Role of Mpl and Imiquimod Adjuvants in Enhancement of Immune Response and Protection in Balb/C Mice Immunized With Soluble Leishmania Antigen (Sla) Encapsulated in Nanoliposome, Artificial Cells# Nanomedicine and Biotechnology (2018)
4. The Role of Lpd-Nanoparticles Containing Recombinant Major Surface Glycoprotein of Leishmania (Rgp63) in Protection Against Leishmaniasis in Murine Model, Immunopharmacology and Immunotoxicology (2018)
5. Cationic Immune Stimulating Complexes Containing Soluble Leishmania Antigens: Preparation, Characterization and in Vivo Immune Response Evaluation, Iranian Journal of Immunology (2015)
6. Multi-Antigen Vaccination With Lpd Nanoparticles Containing Rgp63 and Rlmac1n Proteins Induced Effective Immune Response Against Leishmaniasis in Animal Model, Journal of Drug Delivery Science and Technology (2021)
7. Cationic Liposomes Formulated With a Novel Whole Leishmania Lysate (Wll) As a Vaccine for Leishmaniasis in Murine Model, Immunobiology (2018)
8. Evaluation of Immune Response Against Leishmaniasis in Balb/C Mice Immunized With Cationic Dotap/Dope/Chol Liposomes Containing Soluble Leishmania Major Antigens, Iranian Journal of Parasitology (2019)
Experts (# of related papers)
View all Related Experts
Mahdi Mohebali (9)
Homa Hajjaran (7)
Other Related Docs
9. Coadminstration of L. Major Amastigote Class I Nuclease (Rlmacin) With Lpd Nanoparticles Delays the Progression of Skin Lesion and the L. Major Dissemination to the Spleen in Balb/C Mice-Based Experimental Setting, Acta Tropica (2016)
10. An Overview of Leishmanization Experience: A Successful Control Measure and a Tool to Evaluate Candidate Vaccines, Acta Tropica (2019)
11. Vaccines for Preventing Cutaneous Leishmaniasis, Cochrane Database of Systematic Reviews (2018)
12. Immunization Against Cutaneous Leishmaniasis by Alginate Microspheres Loaded With Autoclaved Leishmania Major (Alm) and Quillaja Saponins, Iranian Journal of Pharmaceutical Research (2016)
13. Sphingomyelin Liposome Bearing Whole Leishmania Lysate Antigens Induce Strong Th2 Immune Response in Balb/C Mice, Iranian Journal of Basic Medical Sciences (2021)
14. Evolution of Antigen-Specific Immune Responses in Cutaneous Leishmaniasis Patients, Parasite Immunology (2021)
15. Double-Blind Randomized Efficacy Field Trial of Alum Precipitated Autoclaved Leishmania Major (Alum-Alm) Vaccine Mixed With Bcg Plus Imiquimod Vs. Placebo Control Group, Iranian Journal of Parasitology (2015)
16. Delivery Systems for Leishmania Vaccine Development, Expert Review of Vaccines (2016)
17. Potential Biomarkers of Immune Protection in Human Leishmaniasis, Medical Microbiology and Immunology (2021)
18. A Phospholipase-A Activity in Soluble Leishmania Antigens Causes Instability of Liposomes, Current Drug Delivery (2020)
19. Comparison of Cytokine Profile of Ifn-Γ, Il-5 and Il-10 in Cutaneous Leishmaniasis Using Pbmc Vs. Whole Blood, Iranian Journal of Microbiology (2019)
20. Gene Expression Analysis of Antimony Resistance in Leishmania Tropica Using Quantitative Real-Time Pcr Focused on Genes Involved in Trypanothione Metabolism and Drug Transport, Archives of Dermatological Research (2019)
21. Correlation Between Clinical Responses With the Drug-Susceptibility of Parasites in Iranian Cutaneous Leishmaniasis Caused by Leishmania Major, Tropical Biomedicine (2017)
22. Recombinant Leishmania Major Lipophosphoglycan 3 Activates Human T-Lymphocytes Via Tlr2-Independent Pathway, Journal of Immunotoxicology (2016)
23. Combinatorial Delivery of Antigen and Tlr Agonists Via Plga Nanoparticles Modulates Leishmania Major-Infected-Macrophages Activation, Biomedicine and Pharmacotherapy (2021)
24. Review of the Prevalence and Causes of Antimony Compounds Resistance in Different Societies: Review Article, Tehran University Medical Journal (2017)
25. Immune Response in Cutaneous Leishmaniasis Patients With Healing Vs. Non-Healing Lesions, Iranian Journal of Microbiology (2020)
26. The Therapeutic Effects of Olive Leaf Extract on Leishmania Major Infection in Balb/C Mice, Marmara Pharmaceutical Journal (2017)
27. Effects of Combined Therapy With Silymarin and Glucantime on Leishmaniasis Induced by Leishmania Major in Balb/C Mice, Drug Research (2015)
28. Mitochondrial Proteome Profiling of Leishmania Tropica, Microbial Pathogenesis (2019)
29. Antimonial Treatment Failure Rate in Patients With Cutaneous Leishmaniasis, Tehran University Medical Journal (2018)
30. Engineering and Design of Promising T-Cell-Based Multi-Epitope Vaccine Candidates Against Leishmaniasis, Scientific Reports (2023)
31. T Helper 1 (Th1), Th2, and Th17 Responses to Leishmania Major Lipophosphoglycan 3, Immunological Investigations (2016)
32. Treatment Failure in Cutaneous Leishmaniasis Patients Referred to the School of Public Health, Tehran University of Medical Sciences During 2008-2017, Journal of Arthropod-Borne Diseases (2020)
33. Overexpression of Iron Super Oxide Dismutases A/B Genes Are Associated With Antimony Resistance of Leishmania Tropica Clinical Isolates, Iranian Journal of Parasitology (2022)
34. A Novel Strategy for Enhance Potentiation of Meglumine Antimoniate Against Leishmania Major in Vitro, Iranian Journal of Parasitology (2019)
35. The Role of Atp-Binding Cassette Transporter Genes Expression in Treatment Failure Cutaneous Leishmaniasis, AMB Express (2022)
36. Expression Analysis of Activated Protein Kinase C Gene (Lack1) in Antimony Sensitive and Resistant Leishmania Tropica Clinical Isolates Using Real-Time Rt-Pcr, International Journal of Dermatology (2016)
37. Development of a Topical Liposomal Formulation of Amphotericin B for the Treatment of Cutaneous Leishmaniasis, International Journal for Parasitology: Drugs and Drug Resistance (2019)
38. Lived Experiences of Patients Suffering From Acute Old World Cutaneous Leishmaniasis: A Qualitative Content Analysis Study From Iran, Journal of Arthropod-Borne Diseases (2018)
39. Insights Into the Trypanothione System in Antimony-Resistant and Sensitive Leishmania Tropica Clinical Isolates, Acta Tropica (2024)
40. Effects of Hydroalcoholic Extract of Glycyrrhiza Glabra and Glycyrrhizic Acid on Promastigote and Amastigote of Leishmania Major (Mrho/Ir/75/Er), Journal of Medicinal Plants (2020)